Open-Label, Single-Center, Phase I Trial to Investigate the Mass Balance and Absolute Bioavailability of the Highly Selective Oral MET Inhibitor Tepotinib in Healthy Volunteers
Investigational New Drugs - Netherlands
doi 10.1007/s10637-020-00926-1
Full Text
Open PDFAbstract
Available in full text
Date
March 27, 2020
Authors
Publisher
Springer Science and Business Media LLC